| 000 | 01768 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250518073718.0 | ||
| 264 | 0 | _c20201111 | |
| 008 | 202011s 0 0 eng d | ||
| 022 | _a2045-2322 | ||
| 024 | 7 |
_a10.1038/s41598-019-55263-y _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPiek, Arnold | |
| 245 | 0 | 0 |
_aPharmacological myeloperoxidase (MPO) inhibition in an obese/hypertensive mouse model attenuates obesity and liver damage, but not cardiac remodeling. _h[electronic resource] |
| 260 |
_bScientific reports _c12 2019 |
||
| 300 |
_a18765 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAngiotensin II _xadministration & dosage |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aDiet, High-Fat _xadverse effects |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 |
_aHeart Ventricles _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension _xblood |
| 650 | 0 | 4 |
_aHypertrophy, Left Ventricular _xblood |
| 650 | 0 | 4 |
_aIntra-Abdominal Fat _xdrug effects |
| 650 | 0 | 4 |
_aLiver _xdrug effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aNon-alcoholic Fatty Liver Disease _xblood |
| 650 | 0 | 4 |
_aObesity _xblood |
| 650 | 0 | 4 |
_aPeroxidase _xantagonists & inhibitors |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 |
_aThioxanthenes _xadministration & dosage |
| 650 | 0 | 4 |
_aVentricular Remodeling _xdrug effects |
| 700 | 1 | _aKoonen, Debby P Y | |
| 700 | 1 | _aSchouten, Elisabeth-Maria | |
| 700 | 1 | _aLindtstedt, Eva L | |
| 700 | 1 | _aMichaëlsson, Erik | |
| 700 | 1 | _ade Boer, Rudolf A | |
| 700 | 1 | _aSilljé, Herman H W | |
| 773 | 0 |
_tScientific reports _gvol. 9 _gno. 1 _gp. 18765 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/s41598-019-55263-y _zAvailable from publisher's website |
| 999 |
_c30406524 _d30406524 |
||